Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Revlimid

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Revlimid was produced by Celgene.

Geron poleaxed as partner J&J abandons only pipeline drug

Geron poleaxed as partner J&J abandons only pipeline drug s broad portfolio headed by Revlimid (lenalidomide), and a clutch of new candidates coming through mid- to late-stage clinical development.

Darzalex powers ahead with frontline myeloma approval in Europe

Darzalex powers ahead with frontline myeloma approval in Europe This is a significant step forward.”. J&J has even more in the pipeline: it's investigating Darzalex as an add-on to regimens based on Celgene’s myeloma blockbuster Revlimid

Celgene’s Revlimid gets a win in late-stage lymphoma

Celgene’s Revlimid gets a win in late-stage lymphoma Patients on Revlimid and Roche’s Rituxan saw boosted PFS rates. Celgene has new phase III data that could add yet another string to blockbuster Revlimid’s bow – as a treatment ... The AUGMENT trial paired Revlimid (lenalidomide) with Roche’s

Drugs for rare diseases will help propel pharma sales to $1.2trn by 2024; report

Drugs for rare diseases will help propel pharma sales to $1.2trn by 2024; report behind Celgene’s cancer immunomodulator Revlimid (lenalidomide).

Safety scuppers combo trials with J&J/Genmab’s Darzalex

Safety scuppers combo trials with J&J/Genmab’s Darzalex Additional studies of Darzalex as an add-on to regimens based on Celgene’s Revlimid (lenalidomide) and in ASCT-eligible patients could further expand the opportunity in previously-untreated patients, says

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics